text:
G protein–coupled receptor
From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
"GPCR" redirects here. It is not to be confused with Great Proletarian Cultural Revolution.
GPCR
The human beta-2 adrenergic receptor in complex with the partial inverse agonist carazolol.[1]
Identifiers
Symbol
7tm_1
Pfam
PF00001
InterPro
IPR000276
PROSITE
PDOC00210
TCDB
9.A.14
OPM superfamily
6
OPM protein
1gzm
showAvailable protein structures:
Pfam
structures
PDB
RCSB PDB; PDBe; PDBj
PDBsum
structure summary
The seven-transmembrane α-helix structure of a G protein–coupled receptor
G protein–coupled receptors (GPCRs), also known as seven-(pass)-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptor, and G protein–linked receptors (GPLR), constitute a large protein family of receptors that detect molecules outside the cell and activate internal signal transduction pathways and, ultimately, cellular responses. Coupling with G proteins, they are called seven-transmembrane receptors because they pass through the cell membrane seven times.[2]
G protein–coupled receptors are found only in eukaryotes, including yeast, choanoflagellates,[3] and animals. The ligands that bind and activate these receptors include light-sensitive compounds, odors, pheromones, hormones, and neurotransmitters, and vary in size from small molecules to peptides to large proteins. G protein–coupled receptors are involved in many diseases, and are also the target of approximately 34% of all modern medicinal drugs.[4][5][6]
There are two principal signal transduction pathways involving the G protein–coupled receptors:
the cAMP signal pathway and
the phosphatidylinositol signal pathway.[7]
When a ligand binds to the GPCR it causes a conformational change in the GPCR, which allows it to act as a guanine nucleotide exchange factor (GEF). The GPCR can then activate an associated G protein by exchanging the GDP bound to the G protein for a GTP. The G protein's α subunit, together with the bound GTP, can then dissociate from the β and γ subunits to further affect intracellular signaling proteins or target functional proteins directly depending on the α subunit type (Gαs, Gαi/o, Gαq/11, Gα12/13).[8]:1160
GPCRs are an important drug target and approximately 34%[9] of all Food and Drug Administration (FDA) approved drugs target this family. The sales volume for these drugs is estimated to be 180 billion US Dollars.[9]
Contents
[hide]
1 History and significance
2 Classification
3 Physiological roles
4 Receptor structure
5 Structure-function relationships
6 Mechanism
6.1 Ligand binding
6.2 Conformational change
6.3 G-protein activation/deactivation cycle
6.4 Crosstalk
7 Signaling
7.1 G-protein-dependent signaling
7.1.1 Gα signaling
7.1.2 Gβγ signaling
7.2 G-protein-independent signaling
7.2.1 Examples
7.2.2 GPCR-independent signaling by heterotrimeric G-proteins
8 Details of cAMP and PIP2 pathways
8.1 cAMP signal pathway
8.2 Phosphatidylinositol signal pathway
9 Receptor regulation
9.1 Phosphorylation by cAMP-dependent protein kinases
9.2 Phosphorylation by GRKs
9.3 Mechanisms of GPCR signal termination
9.4 GPCR cellular regulation
10 Receptor oligomerization
11 Origin and diversification of the superfamily
12 See also
13 References
14 Further reading
15 External links
History and significance[edit]
The 2012 Nobel Prize in Chemistry was awarded to Brian Kobilka and Robert Lefkowitz for their work that was "crucial for understanding how G protein–coupled receptors function".[10] There have been at least seven other Nobel Prizes awarded for some aspect of G protein–mediated signaling.[citation needed] As of 2012, two of the top ten global best-selling drugs (Advair Diskus and Abilify) act by targeting G protein–coupled receptors.[11]
Classification[edit]
Classification Scheme of GPCRs. Class A (Rhodopsin-like), Class B (Secretin-like), Class C (Glutamate Receptor-like), Others (Adhesion (33), Frizzled (11), Taste type-2 (25), unclassified (23)).[12]
The exact size of the GPCR superfamily is unknown, but nearly 800 different human genes (or ~ 4% of the entire protein-coding genome) have been predicted to code for them from genome sequence analysis.[12] Although numerous classification schemes have been proposed, the superfamily was classically divided into three main classes (A, B and C) with no detectable shared sequence homology between classes.
The largest class by far is class A, which accounts for nearly 85% of the GPCR genes. Of class A GPCRs, over half of these are predicted to encode olfactory receptors, while the remaining receptors are liganded by known endogenous compounds or are classified as orphan receptors. Despite the lack of sequence homology between classes, all GPCRs have a common structure and mechanism of signal transduction. The very large rhodopsin A group has been further subdivided into 19 subgroups (A1-A19).[13]
More recently, an alternative classification system called GRAFS (Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, Secretin) has been proposed.[12] According to the classical A-F system, GPCRs can be grouped into 6 classes based on sequence homology and functional similarity:[14][15][16][17]
Class A (or 1) (Rhodopsin-like)
Class B (or 2) (Secretin receptor family)
Class C (or 3) (Metabotropic glutamate/pheromone)
Class D (or 4) (Fungal mating pheromone receptors)
Class E (or 5) (Cyclic AMP receptors)
Class F (or 6) (Frizzled/Smoothened)
An early study based on available DNA sequence suggested that the human genome encodes roughly 750 G protein–coupled receptors,[18] about 350 of which detect hormones, growth factors, and other endogenous ligands. Approximately 150 of the GPCRs found in the human genome have unknown functions.
Some web-servers[19] and bioinformatics prediction methods[20][21] have been used for predicting the classification of GPCRs according to their amino acid sequence alone, by means of the pseudo amino acid composition approach.
Physiological roles[edit]
GPCRs are involved in a wide variety of physiological processes. Some examples of their physiological roles include:
The visual sense: The opsins, gradually evolved from early GPCRs over 650 million years ago, use a photoisomerization reaction to translate electromagnetic radiation into cellular signals. Rhodopsin, for example, uses the conversion of 11-cis-retinal to all-trans-retinal for this purpose.
The gustatory sense (taste): GPCRs in taste cells mediate release of gustducin in response to bitter- and sweet-tasting substances.
The sense of smell: Receptors of the olfactory epithelium bind odorants (olfactory receptors) and pheromones (vomeronasal receptors)
Behavioral and mood regulation: Receptors in the mammalian brain bind several different neurotransmitters, including serotonin, dopamine, GABA, and glutamate
Regulation of immune system activity and inflammation: Chemokine receptors bind ligands that mediate intercellular communication between cells of the immune system; receptors such as histamine receptors bind inflammatory mediators and engage target cell types in the inflammatory response. GPCRs are also involved in immune-modulation and directly involved in suppression of TLR-induced immune responses from T cells.[22]
Autonomic nervous system transmission: Both the sympathetic and parasympathetic nervous systems are regulated by GPCR pathways, responsible for control of many automatic functions of the body such as blood pressure, heart rate, and digestive processes
Cell density sensing: A novel GPCR role in regulating cell density sensing.
Homeostasis modulation (e.g., water balance).[23]
Involved in growth and metastasis of some types of tumors.[24]
Receptor structure[edit]
GPCRs are integral membrane proteins that possess seven membrane-spanning domains or transmembrane helices.[25][26] The extracellular parts of the receptor can be glycosylated. These extracellular loops also contain two highly conserved cysteine residues that form disulfide bonds to stabilize the receptor structure. Some seven-transmembrane helix proteins (channelrhodopsin) that resemble GPCRs may contain ion channels, within their protein.
Similar to GPCRs, the adiponectin receptors 1 and 2 (ADIPOR1 and ADIPOR2) also possess 7 transmembrane domains. However, ADIPOR1 and ADIPOR2 are oriented oppositely to GPCRs in the membrane (i.e. GPCRs usually have an extracellular N-terminus, cytoplasmic C-terminus, whereas ADIPORs are inverted) and do not associate with G proteins.[27]
Early structural models for GPCRs were based on their weak analogy to bacteriorhodopsin, for which a structure had been determined by both electron diffraction (PDB: 2BRD, 1AT9)[28][29] and X ray-based crystallography (1AP9).[30] In 2000, the first crystal structure of a mammalian GPCR, that of bovine rhodopsin (1F88), was solved.[31] While the main feature, the seven-transmembrane helices, is conserved, the relative orientation of the helices differ significantly from that of bacteriorhodopsin. In 2007, the first structure of a human GPCR was solved (2R4R, 2R4S).[32] This was followed immediately by a higher resolution structure of the same receptor (2RH1).[1][33] This human β2-adrenergic receptor GPCR structure proved highly similar to the bovine rhodopsin in terms of the relative orientation of the seven-transmembrane helices. However, the conformation of the second extracellular loop is entirely different between the two structures. Since this loop constitutes the "lid" that covers the top of the ligand binding site, this conformational difference highlights the difficulties in constructing homology models of other GPCRs based only on the rhodopsin structure.
The structures of activated or agonist-bound GPCRs have also been determined.[34][35][36][37] These structures indicate how ligand binding at the extracellular side of a receptor leads to conformational changes in the cytoplasmic side of the receptor. The biggest change is an outward movement of the cytoplasmic part of the 5th and 6th transmembrane helix (TM5 and TM6). The structure of activated beta-2 adrenergic receptor in complex with Gs confirmed that the Gα binds to a cavity created by this movement.[38]
A structure database, GPCR-HGmod, was recently constructed which contains 3D structural models of all human G-protein coupled receptors, built by the GPCR-I-TASSER pipeline[39] through homology modeling and ab initio structure prediction.
Structure-function relationships[edit]
Two-dimensional schematic of a generic GPCR set in a Lipid Raft. Click the image for higher resolution to see details regarding the locations of important structures.
In terms of structure, GPCRs are characterized by an extracellular N-terminus, followed by seven transmembrane (7-TM) α-helices (TM-1 to TM-7) connected by three intracellular (IL-1 to IL-3) and three extracellular loops (EL-1 to EL-3), and finally an intracellular C-terminus. The GPCR arranges itself into a tertiary structure resembling a barrel, with the seven transmembrane helices forming a cavity within the plasma membrane that serves a ligand-binding domain that is often covered by EL-2. Ligands may also bind elsewhere, however, as is the case for bulkier ligands (e.g., proteins or large peptides), which instead interact with the extracellular loops, or, as illustrated by the class C metabotropic glutamate receptors (mGluRs), the N-terminal tail. The class C GPCRs are distinguished by their large N-terminal tail, which also contains a ligand-binding domain. Upon glutamate-binding to an mGluR, the N-terminal tail undergoes a conformational change that leads to its interaction with the residues of the extracellular loops and TM domains. The eventual effect of all three types of agonist-induced activation is a change in the relative orientations of the TM helices (likened to a twisting motion) leading to a wider intracellular surface and "revelation" of residues of the intracellular helices and TM domains crucial to signal transduction function (i.e., G-protein coupling). Inverse agonists and antagonists may also bind to a number of different sites, but the eventual effect must be prevention of this TM helix reorientation.[2]
The structure of the N- and C-terminal tails of GPCRs may also serve important functions beyond ligand-binding. For example, The C-terminus of M3 muscarinic receptors is sufficient, and the six-amino-acid polybasic (KKKRRK) domain in the C-terminus is necessary for its preassembly with Gq proteins.[40] In particular, the C-terminus often contains serine (Ser) or threonine (Thr) residues that, when phosphorylated, increase the affinity of the intracellular surface for the binding of scaffolding proteins called β-arrestins (β-arr).[41] Once bound, β-arrestins both sterically prevent G-protein coupling and may recruit other proteins, leading to the creation of signaling complexes involved in extracellular-signal regulated kinase (ERK) pathway activation or receptor endocytosis (internalization). As the phosphorylation of these Ser and Thr residues often occurs as a result of GPCR activation, the β-arr-mediated G-protein-decoupling and internalization of GPCRs are important mechanisms of desensitization.[42] In addition, internalized "mega-complexes" consisting of a single GPCR, β-arr(in the tail conformation),[43][44] and heterotrimeric G protein exist and may account for protein signaling from endosomes.[45]
A final common structural theme among GPCRs is palmitoylation of one or more sites of the C-terminal tail or the intracellular loops. Palmitoylation is the covalent modification of cysteine (Cys) residues via addition of hydrophobic acyl groups, and has the effect of targeting the receptor to cholesterol- and sphingolipid-rich microdomains of the plasma membrane called lipid rafts. As many of the downstream transducer and effector molecules of GPCRs (including those involved in negative feedback pathways) are also targeted to lipid rafts, this has the effect of facilitating rapid receptor signaling.
GPCRs respond to extracellular signals mediated by a huge diversity of agonists, ranging from proteins to biogenic amines to protons, but all transduce this signal via a mechanism of G-protein coupling. This is made possible by a guanine-nucleotide exchange factor (GEF) domain primarily formed by a combination of IL-2 and IL-3 along with adjacent residues of the associated TM helices.
Mechanism[edit]
Cartoon depicting the basic concept of GPCR Conformational Activation. Ligand binding disrupts an ionic lock between the E/DRY motif of TM-3 and acidic residues of TM-6. As a result, the GPCR reorganizes to allow activation of G-alpha proteins. The side perspective is a view from above and to the side of the GPCR as it is set in the plasma membrane (the membrane lipids have been omitted for clarity). The intracellular perspective shows the view looking up at the plasma membrane from inside the cell.[46]
The G protein–coupled receptor is activated by an external signal in the form of a ligand or other signal mediator. This creates a conformational change in the receptor, causing activation of a G protein. Further effect depends on the type of G protein. G proteins are subsequently inactivated by GTPase activating proteins, known as RGS proteins.
Ligand binding[edit]
GPCRs include one or more receptors for the following ligands: sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine, bombesin, bradykinin, endothelin, γ-aminobutyric acid (GABA), hepatocyte growth factor (HGF), melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, GH, tachykinins, members of the vasoactive intestinal peptide family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine, norepinephrine, histamine, serotonin, and melatonin); glutamate (metabotropic effect); glucagon; acetylcholine (muscarinic effect); chemokines; lipid mediators of inflammation (e.g., prostaglandins, prostanoids, platelet-activating factor, and leukotrienes); peptide hormones (e.g., calcitonin, C5a anaphylatoxin, follicle-stimulating hormone [FSH], gonadotropin-releasing hormone [GnRH], neurokinin, thyrotropin-releasing hormone [TRH], and oxytocin); and endocannabinoids.
GPCRs that act as receptors for stimuli that have not yet been identified are known as orphan receptors.
However, in other types of receptors that have been studied, wherein ligands bind externally to the membrane, the ligands of GPCRs typically bind within the transmembrane domain. However, protease-activated receptors are activated by cleavage of part of their extracellular domain.[47]
Conformational change[edit]
Crystal structure of activated beta-2 adrenergic receptor in complex with Gs(PDB entry 3SN6). The receptor is colored red, Gα green, Gβ cyan, and Gγ yellow. The C-terminus of Gα is located in a cavity created by an outward movement of the cytoplasmic parts of TM5 and 6.
The transduction of the signal through the membrane by the receptor is not completely understood. It is known that in the inactive state, the GPCR is bound to a heterotrimeric G protein complex. Binding of an agonist to the GPCR results in a conformational change in the receptor that is transmitted to the bound Gα subunit of the heterotrimeric G protein via protein domain dynamics. The activated Gα subunit exchanges GTP in place of GDP which in turn triggers the dissociation of Gα subunit from the Gβγ dimer and from the receptor. The dissociated Gα and Gβγ subunits interact with other intracellular proteins to continue the signal transduction cascade while the freed GPCR is able to rebind to another heterotrimeric G protein to form a new complex that is ready to initiate another round of signal transduction.[48]
It is believed that a receptor molecule exists in a conformational equilibrium between active and inactive biophysical states.[49] The binding of ligands to the receptor may shift the equilibrium toward the active receptor states. Three types of ligands exist: Agonists are ligands that shift the equilibrium in favour of active states; inverse agonists are ligands that shift the equilibrium in favour of inactive states; and neutral antagonists are ligands that do not affect the equilibrium. It is not yet known how exactly the active and inactive states differ from each other.
G-protein activation/deactivation cycle[edit]
Cartoon depicting the Heterotrimeric G-protein activation/deactivation cycle in the context of GPCR signaling
See also: G protein
When the receptor is inactive, the GEF domain may be bound to an also inactive α-subunit of a heterotrimeric G-protein. These "G-proteins" are a trimer of α, β, and γ subunits (known as Gα, Gβ, and Gγ, respectively) that is rendered inactive when reversibly bound to Guanosine diphosphate (GDP) (or, alternatively, no guanine nucleotide) but active when bound to Guanosine triphosphate (GTP). Upon receptor activation, the GEF domain, in turn, allosterically activates the G-protein by facilitating the exchange of a molecule of GDP for GTP at the G-protein's α-subunit. The cell maintains a 10:1 ratio of cytosolic GTP:GDP so exchange for GTP is ensured. At this point, the subunits of the G-protein dissociate from the receptor, as well as each other, to yield a Gα-GTP monomer and a tightly interacting Gβγ dimer, which are now free to modulate the activity of other intracellular proteins. The extent to which they may diffuse, however, is limited due to the palmitoylation of Gα and the presence of an isoprenoid moiety that has been covalently added to the C-termini of Gγ.
Because Gα also has slow GTP→GDP hydrolysis capability, the inactive form of the α-subunit (Gα-GDP) is eventually regenerated, thus allowing reassociation with a Gβγ dimer to form the "resting" G-protein, which can again bind to a GPCR and await activation. The rate of GTP hydrolysis is often accelerated due to the actions of another family of allosteric modulating proteins called Regulators of G-protein Signaling, or RGS proteins, which are a type of GTPase-Activating Protein, or GAP. In fact, many of the primary effector proteins (e.g., adenylate cyclases) that become activated/inactivated upon interaction with Gα-GTP also have GAP activity. Thus, even at this early stage in the process, GPCR-initiated signaling has the capacity for self-termination.
Crosstalk[edit]
Proposed downstream interactions between integrin signaling and GPCRs. Integrins are shown elevating Ca2+ and phosphorylating FAK, which is weakening GPCR signaling.
GPCRs downstream signals have been shown to possibly interact with integrin signals, such as FAK.[50] Integrin signaling will phosphorylate FAK, which can then decrease GPCR Gαs activity.
Signaling[edit]
G-protein-coupled receptor mechanism
If a receptor in an active state encounters a G protein, it may activate it. Some evidence suggests that receptors and G proteins are actually pre-coupled.[40] For example, binding of G proteins to receptors affects the receptor's affinity for ligands. Activated G proteins are bound to GTP.
Further signal transduction depends on the type of G protein. The enzyme adenylate cyclase is an example of a cellular protein that can be regulated by a G protein, in this case the G protein Gs. Adenylate cyclase activity is activated when it binds to a subunit of the activated G protein. Activation of adenylate cyclase ends when the G protein returns to the GDP-bound state.
Adenylate cyclases (of which 9 membrane-bound and one cytosolic forms are known in humans) may also be activated or inhibited in other ways (e.g., Ca2+/Calmodulin binding), which can modify the activity of these enzymes in an additive or synergistic fashion along with the G proteins.
The signaling pathways activated through a GPCR are limited by the primary sequence and tertiary structure of the GPCR itself but ultimately determined by the particular conformation stabilized by a particular ligand, as well as the availability of transducer molecules. Currently, GPCRs are considered to utilize two primary types of transducers: G-proteins and β-arrestins. Because β-arr's have high affinity only to the phosphorylated form of most GPCRs (see above or below), the majority of signaling is ultimately dependent upon G-protein activation. However, the possibility for interaction does allow for G-protein-independent signaling to occur.
G-protein-dependent signaling[edit]
There are three main G-protein-mediated signaling pathways, mediated by four sub-classes of G-proteins distinguished from each other by sequence homology (Gαs, Gαi/o, Gαq/11, and Gα12/13). Each sub-class of G-protein consists of multiple proteins, each the product of multiple genes or splice variations that may imbue them with differences ranging from subtle to distinct with regard to signaling properties, but in general they appear reasonably grouped into four classes. Because the signal transducing properties of the various possible βγ combinations do not appear to radically differ from one another, these classes are defined according to the isoform of their α-subunit.[8]:1163
While most GPCRs are capable of activating more than one Gα-subtype, they also show a preference for one subtype over another. When the subtype activated depends on the ligand that is bound to the GPCR, this is called functional selectivity (also known as agonist-directed trafficking, or conformation-specific agonism). However, the binding of any single particular agonist may also initiate activation of multiple different G-proteins, as it may be capable of stabilizing more than one conformation of the GPCR's GEF domain, even over the course of a single interaction. In addition, a conformation that preferably activates one isoform of Gα may activate another if the preferred is less available. Furthermore, feedback pathways may result in receptor modifications (e.g., phosphorylation) that alter the G-protein preference. Regardless of these various nuances, the GPCR's preferred coupling partner is usually defined according to the G-protein most obviously activated by the endogenous ligand under most physiological or experimental conditions.
Gα signaling[edit]
The effector of both the Gαs and Gαi/o pathways is the cyclic-adenosine monophosphate (cAMP)-generating enzyme adenylate cyclase, or AC. While there are ten different AC gene products in mammals, each with subtle differences in tissue distribution or function, all catalyze the conversion of cytosolic adenosine triphosphate (ATP) to cAMP, and all are directly stimulated by G-proteins of the Gαs class. In contrast, however, interaction with Gα subunits of the Gαi/o type inhibits AC from generating cAMP. Thus, a GPCR coupled to Gαs counteracts the actions of a GPCR coupled to Gαi/o, and vice versa. The level of cytosolic cAMP may then determine the activity of various ion channels as well as members of the ser/thr-specific protein kinase A (PKA) family. Thus cAMP is considered a second messenger and PKA a secondary effector.
The effector of the Gαq/11 pathway is phospholipase C-β (PLCβ), which catalyzes the cleavage of membrane-bound phosphatidylinositol 4,5-biphosphate (PIP2) into the second messengers inositol (1,4,5) trisphosphate (IP3) and diacylglycerol (DAG). IP3 acts on IP3 receptors found in the membrane of the endoplasmic reticulum (ER) to elicit Ca2+ release from the ER, while DAG diffuses along the plasma membrane where it may activate any membrane localized forms of a second ser/thr kinase called protein kinase C (PKC). Since many isoforms of PKC are also activated by increases in intracellular Ca2+, both these pathways can also converge on each other to signal through the same secondary effector. Elevated intracellular Ca2+ also binds and allosterically activates proteins called calmodulins, which in turn go on to bind and allosterically activate enzymes such as Ca2+/calmodulin-dependent kinases (CAMKs).
The effectors of the Gα12/13 pathway are three RhoGEFs (p115-RhoGEF, PDZ-RhoGEF, and LARG), which, when bound to Gα12/13 allosterically activate the cytosolic small GTPase, Rho. Once bound to GTP, Rho can then go on to activate various proteins responsible for cytoskeleton regulation such as Rho-kinase (ROCK). Most GPCRs that couple to Gα12/13 also couple to other sub-classes, often Gαq/11.
Gβγ signaling[edit]
The above descriptions ignore the effects of Gβγ–signalling, which can also be important, in particular in the case of activated Gαi/o-coupled GPCRs. The primary effectors of Gβγ are various ion channels, such as G-protein-regulated inwardly rectifying K+ channels (GIRKs), P/Q- and N-type voltage-gated Ca2+ channels, as well as some isoforms of AC and PLC, along with some phosphoinositide-3-kinase (PI3K) isoforms.
G-protein-independent signaling[edit]
Although they are classically thought of working only together, GPCRs may signal through G-protein-independent mechanisms, and heterotrimeric G-proteins may play functional roles independent of GPCRs. GPCRs may signal independently through many proteins already mentioned for their roles in G-protein-dependent signaling such as β-arrs, GRKs, and Srcs. In addition, further scaffolding proteins involved in subcellular localization of GPCRs (e.g., PDZ-domain-containing proteins) may also act as signal transducers. Most often the effector is a member of the MAPK family.
Examples[edit]
In the late 1990s, evidence began accumulating to suggest that some GPCRs are able to signal without G proteins. The ERK2 mitogen-activated protein kinase, a key signal transduction mediator downstream of receptor activation in many pathways, has been shown to be activated in response to cAMP-mediated receptor activation in the slime mold D. discoideum despite the absence of the associated G protein α- and β-subunits.[51]
In mammalian cells, the much-studied β2-adrenoceptor has been demonstrated to activate the ERK2 pathway after arrestin-mediated uncoupling of G-protein-mediated signaling. Therefore, it seems likely that some mechanisms previously believed related purely to receptor desensitisation are actually examples of receptors switching their signaling pathway, rather than simply being switched off.
In kidney cells, the bradykinin receptor B2 has been shown to interact directly with a protein tyrosine phosphatase. The presence of a tyrosine-phosphorylated ITIM (immunoreceptor tyrosine-based inhibitory motif) sequence in the B2 receptor is necessary to mediate this interaction and subsequently the antiproliferative effect of bradykinin.[52]
GPCR-independent signaling by heterotrimeric G-proteins[edit]
Although it is a relatively immature area of research, it appears that heterotrimeric G-proteins may also take part in non-GPCR signaling. There is evidence for roles as signal transducers in nearly all other types of receptor-mediated signaling, including integrins, receptor tyrosine kinases (RTKs), cytokine receptors (JAK/STATs), as well as modulation of various other "accessory" proteins such as GEFs, guanine-nucleotide dissociation inhibitors (GDIs) and protein phosphatases. There may even be specific proteins of these classes whose primary function is as part of GPCR-independent pathways, termed activators of G-protein signalling (AGS). Both the ubiquity of these interactions and the importance of Gα vs. Gβγ subunits to these processes are still unclear.
Details of cAMP and PIP2 pathways[edit]
Activation effects of cAMP on protein kinase A
The effect of Rs and Gs in cAMP signal pathway
The effect of Ri and Gi in cAMP signal pathway
There are two principal signal transduction pathways involving the G protein-linked receptors: the cAMP signal pathway and the phosphatidylinositol signal pathway.[7]
cAMP signal pathway[edit]
Main article: cAMP-dependent pathway
The cAMP signal transduction contains 5 main characters: stimulative hormone receptor (Rs) or inhibitory hormone receptor (Ri); stimulative regulative G-protein (Gs) or inhibitory regulative G-protein (Gi); adenylyl cyclase; protein kinase A (PKA); and cAMP phosphodiesterase.
Stimulative hormone receptor (Rs) is a receptor that can bind with stimulative signal molecules, while inhibitory hormone receptor (Ri) is a receptor that can bind with inhibitory signal molecules.
Stimulative regulative G-protein is a G-protein linked to stimulative hormone receptor (Rs), and its α subunit upon activation could stimulate the activity of an enzyme or other intracellular metabolism. On the contrary, inhibitory regulative G-protein is linked to an inhibitory hormone receptor, and its α subunit upon activation could inhibit the activity of an enzyme or other intracellular metabolism.
Adenylyl cyclase is a 12-transmembrane glycoprotein that catalyzes ATP to form cAMP with the help of cofactor Mg2+ or Mn2+. The cAMP produced is a second messenger in cellular metabolism and is an allosteric activator of protein kinase A.
Protein kinase A is an important enzyme in cell metabolism due to its ability to regulate cell metabolism by phosphorylating specific committed enzymes in the metabolic pathway. It can also regulate specific gene expression, cellular secretion, and membrane permeability. The protein enzyme contains two catalytic subunits and two regulatory subunits. When there is no cAMP，the complex is inactive. When cAMP binds to the regulatory subunits, their conformation is altered, causing the dissociation of the regulatory subunits, which activates protein kinase A and allows further biological effects.
These signals then can be terminated by cAMP phosphodiesterase, which is an enzyme that degrades cAMP to 5'-AMP and inactivates protein kinase A.
Phosphatidylinositol signal pathway[edit]
Main article: IP3/DAG pathway
In the phosphatidylinositol signal pathway, the extracellular signal molecule binds with the G-protein receptor (Gq) on the cell surface and activates phospholipase C, which is located on the plasma membrane. The lipase hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds with the IP3 receptor in the membrane of the smooth endoplasmic reticulum and mitochondria to open Ca2+ channels. DAG helps activate protein kinase C (PKC), which phosphorylates many other proteins, changing their catalytic activities, leading to cellular responses.
The effects of Ca2+ are also remarkable: it cooperates with DAG in activating PKC and can activate the CaM kinase pathway, in which calcium-modulated protein calmodulin (CaM) binds Ca2+, undergoes a change in conformation, and activates CaM kinase II, which has unique ability to increase its binding affinity to CaM by autophosphorylation, making CaM unavailable for the activation of other enzymes. The kinase then phosphorylates target enzymes, regulating their activities. The two signal pathways are connected together by Ca2+-CaM, which is also a regulatory subunit of adenylyl cyclase and phosphodiesterase in the cAMP signal pathway.
Receptor regulation[edit]
GPCRs become desensitized when exposed to their ligand for a long period of time. There are two recognized forms of desensitization: 1) homologous desensitization, in which the activated GPCR is downregulated; and 2) heterologous desensitization, wherein the activated GPCR causes downregulation of a different GPCR. The key reaction of this downregulation is the phosphorylation of the intracellular (or cytoplasmic) receptor domain by protein kinases.
Phosphorylation by cAMP-dependent protein kinases[edit]
Cyclic AMP-dependent protein kinases (protein kinase A) are activated by the signal chain coming from the G protein (that was activated by the receptor) via adenylate cyclase and cyclic AMP (cAMP). In a feedback mechanism, these activated kinases phosphorylate the receptor. The longer the receptor remains active the more kinases are activated and the more receptors are phosphorylated. In β2-adrenoceptors, this phosphorylation results in the switching of the coupling from the Gs class of G-protein to the Gi class.[53] cAMP-dependent PKA mediated phosphorylation can cause heterologous desensitisation in receptors other than those activated.[54]
Phosphorylation by GRKs[edit]
The G protein-coupled receptor kinases (GRKs) are protein kinases that phosphorylate only active GPCRs.[55] G-protein-coupled receptor kinases (GRKs) are key modulators of G-protein-coupled receptor (GPCR) signaling. They constitute a family of seven mammalian serine-threonine protein kinases that phosphorylate agonist-bound receptor. GRKs-mediated receptor phosphorylation rapidly initiates profound impairment of receptor signaling and desensitization. Activity of GRKs and subcellular targeting is tightly regulated by interaction with receptor domains, G protein subunits, lipids, anchoring proteins and calcium-sensitive proteins.[56]
Phosphorylation of the receptor can have two consequences:
Translocation: The receptor is, along with the part of the membrane it is embedded in, brought to the inside of the cell, where it is dephosphorylated within the acidic vesicular environment[57] and then brought back. This mechanism is used to regulate long-term exposure, for example, to a hormone, by allowing resensitisation to follow desensitisation. Alternatively, the receptor may undergo lysozomal degradation, or remain internalised, where it is thought to participate in the initiation of signalling events, the nature of which depending on the internalised vesicle's subcellular localisation.[54]
Arrestin linking: The phosphorylated receptor can be linked to arrestin molecules that prevent it from binding (and activating) G proteins, in effect switching it off for a short period of time. This mechanism is used, for example, with rhodopsin in retina cells to compensate for exposure to bright light. In many cases, arrestin's binding to the receptor is a prerequisite for translocation. For example, beta-arrestin bound to β2-adrenoreceptors acts as an adaptor for binding with clathrin, and with the beta-subunit of AP2 (clathrin adaptor molecules); thus, the arrestin here acts as a scaffold assembling the components needed for clathrin-mediated endocytosis of β2-adrenoreceptors.[58][59]
Mechanisms of GPCR signal termination[edit]
As mentioned above, G-proteins may terminate their own activation due to their intrinsic GTP→GDP hydrolysis capability. However, this reaction proceeds at a slow rate (≈.02 times/sec) and, thus, it would take around 50 seconds for any single G-protein to deactivate if other factors did not come into play. Indeed, there are around 30 isoforms of RGS proteins that, when bound to Gα through their GAP domain, accelerate the hydrolysis rate to ≈30 times/sec. This 1500-fold increase in rate allows for the cell to respond to external signals with high speed, as well as spatial resolution due to limited amount of second messenger that can be generated and limited distance a G-protein can diffuse in .03 seconds. For the most part, the RGS proteins are promiscuous in their ability to activate G-proteins, while which RGS is involved in a given signaling pathway seems more determined by the tissue and GPCR involved than anything else. In addition, RGS proteins have the additional function of increasing the rate of GTP-GDP exchange at GPCRs, (i.e., as a sort of co-GEF) further contributing to the time resolution of GPCR signaling.
In addition, the GPCR may be desensitized itself. This can occur as:
a direct result of ligand occupation, wherein the change in conformation allows recruitment of GPCR-Regulating Kinases (GRKs), which go on to phosphorylate various serine/threonine residues of IL-3 and the C-terminal tail. Upon GRK phosphorylation, the GPCR's affinity for β-arrestin (β-arrestin-1/2 in most tissues) is increased, at which point β-arrestin may bind and act to both sterically hinder G-protein coupling as well as initiate the process of receptor internalization through clathrin-mediated endocytosis. Because only the liganded receptor is desensitized by this mechanism, it is called homologous desensitization
the affinity for β-arrestin may be increased in a ligand occupation and GRK-independent manner through phosphorylation of different ser/thr sites (but also of IL-3 and the C-terminal tail) by PKC and PKA. These phosphorylations are often sufficient to impair G-protein coupling on their own as well.[citation needed]
PKC/PKA may, instead, phosphorylate GRKs, which can also lead to GPCR phosphorylation and β-arrestin binding in an occupation-independent manner. These latter two mechanisms allow for desensitization of one GPCR due to the activities of others, or heterologous desensitization. GRKs may also have GAP domains and so may contribute to inactivation through non-kinase mechanisms as well. A combination of these mechanisms may also occur.
Once β-arrestin is bound to a GPCR, it undergoes a conformational change allowing it to serve as a scaffolding protein for an adaptor complex termed AP-2, which in turn recruits another protein called clathrin. If enough receptors in the local area recruit clathrin in this manner, they aggregate and the membrane buds inwardly as a result of interactions between the molecules of clathrin, in a process called opsonization. Once the pit has been pinched off the plasma membrane due to the actions of two other proteins called amphiphysin and dynamin, it is now an endocytic vesicle. At this point, the adapter molecules and clathrin have dissociated, and the receptor is either trafficked back to the plasma membrane or targeted to lysosomes for degradation.
At any point in this process, the β-arrestins may also recruit other proteins—such as the non-receptor tyrosine kinase (nRTK), c-SRC—which may activate ERK1/2, or other mitogen-activated protein kinase (MAPK) signaling through, for example, phosphorylation of the small GTP-ase, Ras, or recruit the proteins of the ERK cascade directly (i.e., Raf-1, MEK, ERK-1/2) at which point signaling is initiated due to their close proximity to one another. Another target of c-SRC are the dynamin molecules involved in endocytosis. Dynamins polymerize around the neck of an incoming vesicle, and their phosphorylation by c-SRC provides the energy necessary for the conformational change allowing the final "pinching off" from the membrane.
GPCR cellular regulation[edit]
Receptor desensitization is mediated through a combination phosphorylation, β-arr binding, and endocytosis as described above. Downregulation occurs when endocytosed receptor is embedded in an endosome that is trafficked to merge with an organelle called a lysosome. Because lysosomal membranes are rich in proton pumps, their interiors have low pH (≈4.8 vs. the pH≈7.2 cytosol), which acts to denature the GPCRs. In addition, lysosomes contain many degradative enzymes, including proteases, which can function only at such low pH, and so the peptide bonds joining the residues of the GPCR together may be cleaved. Whether or not a given receptor is trafficked to a lysosome, detained in endosomes, or trafficked back to the plasma membrane depends on a variety of factors, including receptor type and magnitude of the signal. GPCR regulation is additionally mediated by gene transcription factors. These factors can increase or decrease gene transcription and thus increase or decrease the generation of new receptors (up- or down-regulation) that travel to the cell membrane.
Receptor oligomerization[edit]
Main article: GPCR oligomer
G-protein-coupled receptor oligomerisation is a widespread phenomenon. One of the best-studied examples is the metabotropic GABAB receptor. This so-called constitutive receptor is formed by heterodimerization of GABABR1 and GABABR2 subunits. Expression of the GABABR1 without the GABABR2 in heterologous systems leads to retention of the subunit in the endoplasmic reticulum. Expression of the GABABR2 subunit alone, meanwhile, leads to surface expression of the subunit, although with no functional activity (i.e., the receptor does not bind agonist and cannot initiate a response following exposure to agonist). Expression of the two subunits together leads to plasma membrane expression of functional receptor. It has been shown that GABABR2 binding to GABABR1 causes masking of a retention signal[60] of functional receptors.[61]
Origin and diversification of the superfamily[edit]
Signal transduction mediated by the superfamily of GPCRs dates back to the origin of multicellularity. Mammalian-like GPCRs are found in fungi, and have been classified according to the GRAFS classification system based on GPCR fingerprints.[62] Identification of the superfamily members across the eukaryotic domain, and comparison of the family-specific motifs, have shown that the superfamily of GPCRs have a common origin.[63] Characteristic motifs indicate that three of the five GRAFS families, Rhodopsin, Adhesion, and Frizzled, evolved from the Dictyostelium discoideum cAMP receptors before the split of Opisthokonts. Later, the Secretin family evolved from the Adhesion GPCR receptor family before the split of nematodes.
See also[edit]
G protein-coupled receptors database
List of MeSH codes (D12.776)
Metabotropic receptor
Orphan receptor
Pepducins, a class of drug candidates targeted at GPCRs
Receptor activated solely by a synthetic ligand, a technique for control of cell signaling through synthetic GPCRs
TOG superfamily
References[edit]
^ Jump up to: a b Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC (November 2007). "High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor". Science. 318 (5854): 1258–65. doi:10.1126/science.1150577. PMC 2583103  . PMID 17962520.
^ Jump up to: a b Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S (2012). "Action of molecular switches in GPCRs—theoretical and experimental studies". Current Medicinal Chemistry. 19 (8): 1090–109. doi:10.2174/092986712799320556. PMC 3343417  . PMID 22300046.
Jump up ^ King N, Hittinger CT, Carroll SB (July 2003). "Evolution of key cell signaling and adhesion protein families predates animal origins". Science. 301 (5631): 361–3. doi:10.1126/science.1083853. PMID 12869759.
Jump up ^ Filmore D (2004). "It's a GPCR world". Modern Drug Discovery. American Chemical Society. 2004 (November): 24–28.
Jump up ^ Overington JP, Al-Lazikani B, Hopkins AL (December 2006). "How many drug targets are there?". Nature Reviews. Drug Discovery. 5 (12): 993–6. doi:10.1038/nrd2199. PMID 17139284.
Jump up ^ Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE (December 2017). "Trends in GPCR drug discovery: new agents, targets and indications". Nature Reviews. Drug Discovery. 16 (12): 829–842. doi:10.1038/nrd.2017.178. PMID 29075003.
^ Jump up to: a b Gilman AG (1987). "G proteins: transducers of receptor-generated signals". Annual Review of Biochemistry. 56 (1): 615–49. doi:10.1146/annurev.bi.56.070187.003151. PMID 3113327.
^ Jump up to: a b Wettschureck N, Offermanns S (October 2005). "Mammalian G proteins and their cell type specific functions". Physiological Reviews. 85 (4): 1159–204. doi:10.1152/physrev.00003.2005. PMID 16183910.
^ Jump up to: a b Hauser AS, Chavali S, Masuho I, Jahn LJ, Martemyanov KA, Gloriam DE, Babu MM (January 2018). "Pharmacogenomics of GPCR Drug Targets". Cell. 172 (1-2): 41–54.e19. doi:10.1016/j.cell.2017.11.033. PMC 5766829  . PMID 29249361.
Jump up ^ Royal Swedish Academy of Sciences (10 October 2012). "The Nobel Prize in Chemistry 2012 Robert J. Lefkowitz, Brian K. Kobilka". Retrieved 10 October 2012.
Jump up ^ "The Top Prescription Drugs of 2012 Globally: Biologics Dominate, But Small Molecule CNS Drugs Hold on to Top Spots" (PDF). ACS Chemical Neuroscience. Retrieved 3 February 2016.
^ Jump up to: a b c Bjarnadóttir TK, Gloriam DE, Hellstrand SH, Kristiansson H, Fredriksson R, Schiöth HB (September 2006). "Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse". Genomics. 88 (3): 263–73. doi:10.1016/j.ygeno.2006.04.001. PMID 16753280.
Jump up ^ Joost P, Methner A (October 2002). "Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands". Genome Biology. 3 (11): RESEARCH0063. doi:10.1186/gb-2002-3-11-research0063. PMC 133447  . PMID 12429062.
Jump up ^ Attwood TK, Findlay JB (February 1994). "Fingerprinting G-protein-coupled receptors". Protein Engineering. 7 (2): 195–203. doi:10.1093/protein/7.2.195. PMID 8170923.
Jump up ^ Kolakowski LF (1994). "GCRDb: a G-protein-coupled receptor database". Receptors & Channels. 2 (1): 1–7. PMID 8081729.
Jump up ^ Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, Spedding M, Harmar AJ (June 2005). "International Union of Pharmacology. XLVI. G protein-coupled receptor list". Pharmacological Reviews. 57 (2): 279–88. doi:10.1124/pr.57.2.5. PMID 15914470.
Jump up ^ InterPro
Jump up ^ Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller JR, Wright AC, Bergmann JE, Gaitanaris GA (April 2003). "The G protein-coupled receptor repertoires of human and mouse". Proceedings of the National Academy of Sciences of the United States of America. 100 (8): 4903–8. doi:10.1073/pnas.0230374100. PMC 153653  . PMID 12679517.
Jump up ^ Xiao X, Wang P, Chou KC (July 2009). "GPCR-CA: A cellular automaton image approach for predicting G-protein-coupled receptor functional classes". Journal of Computational Chemistry. 30 (9): 1414–23. doi:10.1002/jcc.21163. PMID 19037861. [permanent dead link]
Jump up ^ Qiu JD, Huang JH, Liang RP, Lu XQ (July 2009). "Prediction of G-protein-coupled receptor classes based on the concept of Chou's pseudo amino acid composition: an approach from discrete wavelet transform". Analytical Biochemistry. 390 (1): 68–73. doi:10.1016/j.ab.2009.04.009. PMID 19364489.
Jump up ^ Gu Q, Ding YS, Zhang TL (May 2010). "Prediction of G-protein-coupled receptor classes in low homology using Chou's pseudo amino acid composition with approximate entropy and hydrophobicity patterns". Protein and Peptide Letters. 17 (5): 559–67. doi:10.2174/092986610791112693. PMID 19594431.
Jump up ^ Sharma N, Akhade AS, Qadri A (April 2013). "Sphingosine-1-phosphate suppresses TLR-induced CXCL8 secretion from human T cells". Journal of Leukocyte Biology. 93 (4): 521–8. doi:10.1189/jlb.0712328. PMID 23345392.
Jump up ^ Hazell GG, Hindmarch CC, Pope GR, Roper JA, Lightman SL, Murphy D, O'Carroll AM, Lolait SJ (January 2012). "G protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei—serpentine gateways to neuroendocrine homeostasis". Frontiers in Neuroendocrinology. 33 (1): 45–66. doi:10.1016/j.yfrne.2011.07.002. PMC 3336209  . PMID 21802439.
Jump up ^ Dorsam RT, Gutkind JS (February 2007). "G-protein-coupled receptors and cancer". Nature Reviews. Cancer. 7 (2): 79–94. doi:10.1038/nrc2069. PMID 17251915.
Jump up ^ Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM (February 2013). "Molecular signatures of G-protein-coupled receptors". Nature. 494 (7436): 185–94. doi:10.1038/nature11896. PMID 23407534.
Jump up ^ Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC (January 2014). "Insights into the structure of class B GPCRs". Trends in Pharmacological Sciences. 35 (1): 12–22. doi:10.1016/j.tips.2013.11.001. PMC 3931419  . PMID 24359917.
Jump up ^ Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (June 2003). "Cloning of adiponectin receptors that mediate antidiabetic metabolic effects". Nature. 423 (6941): 762–9. doi:10.1038/nature01705. PMID 12802337.
Jump up ^ Grigorieff N, Ceska TA, Downing KH, Baldwin JM, Henderson R (June 1996). "Electron-crystallographic refinement of the structure of bacteriorhodopsin". Journal of Molecular Biology. 259 (3): 393–421. doi:10.1006/jmbi.1996.0328. PMID 8676377.
Jump up ^ Kimura Y, Vassylyev DG, Miyazawa A, Kidera A, Matsushima M, Mitsuoka K, Murata K, Hirai T, Fujiyoshi Y (September 1997). "Surface of bacteriorhodopsin revealed by high-resolution electron crystallography". Nature. 389 (6647): 206–11. doi:10.1038/38323. PMID 9296502.
Jump up ^ Pebay-Peyroula E, Rummel G, Rosenbusch JP, Landau EM (September 1997). "X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases". Science. 277 (5332): 1676–81. doi:10.1126/science.277.5332.1676. PMID 9287223.
Jump up ^ Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M (August 2000). "Crystal structure of rhodopsin: A G protein-coupled receptor" (PDF). Science. 289 (5480): 739–45. doi:10.1126/science.289.5480.739. PMID 10926528.
Jump up ^ Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK (November 2007). "Crystal structure of the human beta2 adrenergic G-protein-coupled receptor". Nature. 450 (7168): 383–7. doi:10.1038/nature06325. PMID 17952055.
Jump up ^ Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK (November 2007). "GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function". Science. 318 (5854): 1266–73. doi:10.1126/science.1150609. PMID 17962519.
Jump up ^ Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK (January 2011). "Structure of a nanobody-stabilized active state of the β(2) adrenoceptor". Nature. 469 (7329): 175–80. doi:10.1038/nature09648. PMC 3058308  . PMID 21228869.
Jump up ^ Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, Sunahara RK, Chae PS, Gellman SH, Dror RO, Shaw DE, Weis WI, Caffrey M, Gmeiner P, Kobilka BK (January 2011). "Structure and function of an irreversible agonist-β(2) adrenoceptor complex". Nature. 469 (7329): 236–40. doi:10.1038/nature09665. PMC 3074335  . PMID 21228876.
Jump up ^ Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, Leslie AG, Schertler GF, Tate CG (January 2011). "The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor". Nature. 469 (7329): 241–4. doi:10.1038/nature09746. PMC 3023143  . PMID 21228877.
Jump up ^ Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC (April 2011). "Structure of an agonist-bound human A2A adenosine receptor". Science. 332 (6027): 322–7. doi:10.1126/science.1202793. PMC 3086811  . PMID 21393508.
Jump up ^ Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah ST, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara RK, Kobilka BK (September 2011). "Crystal structure of the β2 adrenergic receptor-Gs protein complex". Nature. 477 (7366): 549–55. doi:10.1038/nature10361. PMC 3184188  . PMID 21772288.
Jump up ^ Zhang J, Yang J, Jang R, Zhang Y (August 2015). "GPCR-I-TASSER: A Hybrid Approach to G Protein-Coupled Receptor Structure Modeling and the Application to the Human Genome". Structure. 23: 1538–49. doi:10.1016/j.str.2015.06.007. PMC 4526412  . PMID 26190572.
^ Jump up to: a b Qin K, Dong C, Wu G, Lambert NA (October 2011). "Inactive-state preassembly of G(q)-coupled receptors and G(q) heterotrimers". Nature Chemical Biology. 7 (10): 740–7. doi:10.1038/nchembio.642. PMC 3177959  . PMID 21873996.
Jump up ^ Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ (June 1990). "beta-Arrestin: a protein that regulates beta-adrenergic receptor function". Science. 248 (4962): 1547–50. doi:10.1126/science.2163110. PMID 2163110.
Jump up ^ Luttrell LM, Lefkowitz RJ (February 2002). "The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals". Journal of Cell Science. 115 (Pt 3): 455–65. PMID 11861753.
Jump up ^ Cahill TJ 3rd, Thomsen AR, Tarrasch JT, Plouffe B, Nguyen AH, Yang F, Huang LY, Kahsai AW, Bassoni DL, Gavino BJ, Lamerdin JE, Triest S, Shukla AK, Berger B, Little J 4th, Antar A, Blanc A, Qu CX, Chen X, Kawakami K, Inoue A, Aoki J, Steyaert J, Sun JP, Bouvier M, Skiniotis G, Lefkowitz RJ (2017). "Distinct conformations of GPCR–β-arrestin complexes mediate desensitization, signaling, and endocytosis". PNAS. 114: 2562–2567. doi:10.1073/pnas.1701529114. PMC 5347553  . PMID 28223524.
Jump up ^ Kumari P, Srivastava A, Banerjee R, Ghosh E, Gupta P, Ranjan R, Chen X, Gupta B, Gupta C, Jaiman D, Shukla AK (November 2016). "Functional competence of a partially engaged GPCR-β-arrestin complex". Nature Communications. 7: 13416. doi:10.1038/ncomms13416. PMC 5105198  . PMID 27827372.
Jump up ^ Thomsen AR, Plouffe B, Cahill TJ, Shukla AK, Tarrasch JT, Dosey AM, Kahsai AW, Strachan RT, Pani B, Mahoney JP, Huang L, Breton B, Heydenreich FM, Sunahara RK, Skiniotis G, Bouvier M, Lefkowitz RJ (2016). "GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling". Cell. 166: 907–19. doi:10.1016/j.cell.2016.07.004. PMID 27499021.
Jump up ^ Millar RP, Newton CL (January 2010). "The year in G protein-coupled receptor research". Mol. Endocrinol. 24 (1): 261–74. doi:10.1210/me.2009-0473. PMID 20019124.
Jump up ^ Brass LF (September 2003). "Thrombin and platelet activation". Chest. 124 (3 Suppl): 18S–25S. doi:10.1378/chest.124.3_suppl.18S. PMID 12970120.
Jump up ^ Digby GJ, Lober RM, Sethi PR, Lambert NA (November 2006). "Some G protein heterotrimers physically dissociate in living cells". Proceedings of the National Academy of Sciences of the United States of America. 103 (47): 17789–94. doi:10.1073/pnas.0607116103. PMC 1693825  . PMID 17095603.
Jump up ^ Rubenstein LA, Lanzara RG (1998). "Activation of G protein-coupled receptors entails cysteine modulation of agonist binding". Journal of Molecular Structure (Theochem). 430: 57–71. doi:10.1016/S0166-1280(98)90217-2.
Jump up ^ Teoh CM, Tam JK, Tran T (2012). "Integrin and GPCR Crosstalk in the Regulation of ASM Contraction Signaling in Asthma". Journal of Allergy. 2012: 341282. doi:10.1155/2012/341282. PMC 3465959  . PMID 23056062.
Jump up ^ Kim JY, Haastert PV, Devreotes PN (April 1996). "Social senses: G-protein-coupled receptor signaling pathways in Dictyostelium discoideum". Chemistry & Biology. 3 (4): 239–43. doi:10.1016/S1074-5521(96)90103-9. PMID 8807851.
Jump up ^ Duchene J, Schanstra JP, Pecher C, Pizard A, Susini C, Esteve JP, Bascands JL, Girolami JP (October 2002). "A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation". The Journal of Biological Chemistry. 277 (43): 40375–83. doi:10.1074/jbc.M202744200. PMID 12177051.
Jump up ^ Chen-Izu Y, Xiao RP, Izu LT, Cheng H, Kuschel M, Spurgeon H, Lakatta EG (November 2000). "G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels". Biophysical Journal. 79 (5): 2547–56. doi:10.1016/S0006-3495(00)76495-2. PMC 1301137  . PMID 11053129.
^ Jump up to: a b Tan CM, Brady AE, Nickols HH, Wang Q, Limbird LE (2004). "Membrane trafficking of G protein-coupled receptors". Annual Review of Pharmacology and Toxicology. 44 (1): 559–609. doi:10.1146/annurev.pharmtox.44.101802.121558. PMID 14744258.
Jump up ^ Santulli G, Trimarco B, Iaccarino G (March 2013). "G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms". High Blood Pressure & Cardiovascular Prevention. 20 (1): 5–12. doi:10.1007/s40292-013-0001-8. PMID 23532739.
Jump up ^ Penela P, Ribas C, Mayor F (November 2003). "Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases". Cellular Signalling. 15 (11): 973–81. doi:10.1016/S0898-6568(03)00099-8. PMID 14499340.
Jump up ^ Krueger KM, Daaka Y, Pitcher JA, Lefkowitz RJ (January 1997). "The role of sequestration in G protein-coupled receptor resensitization. Regulation of beta2-adrenergic receptor dephosphorylation by vesicular acidification". The Journal of Biological Chemistry. 272 (1): 5–8. doi:10.1074/jbc.272.1.5. PMID 8995214.
Jump up ^ Laporte SA, Oakley RH, Holt JA, Barak LS, Caron MG (July 2000). "The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits" (PDF). The Journal of Biological Chemistry. 275 (30): 23120–6. doi:10.1074/jbc.M002581200. PMID 10770944.
Jump up ^ Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG, Barak LS (March 1999). "The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis". Proceedings of the National Academy of Sciences of the United States of America. 96 (7): 3712–7. doi:10.1073/pnas.96.7.3712. PMC 22359  . PMID 10097102.
Jump up ^ Margeta-Mitrovic M, Jan YN, Jan LY (July 2000). "A trafficking checkpoint controls GABA(B) receptor heterodimerization". Neuron. 27 (1): 97–106. doi:10.1016/S0896-6273(00)00012-X. PMID 10939334.
Jump up ^ White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, Barnes AA, Emson P, Foord SM, Marshall FH (December 1998). "Heterodimerization is required for the formation of a functional GABA(B) receptor". Nature. 396 (6712): 679–82. doi:10.1038/25354. PMID 9872316.
Jump up ^ Krishnan A, Almén MS, Fredriksson R, Schiöth HB (2012). Xue C, ed. "The origin of GPCRs: identification of mammalian like Rhodopsin, Adhesion, Glutamate and Frizzled GPCRs in fungi". PLOS ONE. 7 (1): e29817. doi:10.1371/journal.pone.0029817. PMC 3251606  . PMID 22238661.
Jump up ^ Nordström KJ, Sällman Almén M, Edstam MM, Fredriksson R, Schiöth HB (September 2011). "Independent HHsearch, Needleman—Wunsch-based, and motif analyses reveal the overall hierarchy for most of the G protein-coupled receptor families". Molecular Biology and Evolution. 28 (9): 2471–80. doi:10.1093/molbev/msr061. PMID 21402729.
Further reading[edit]
Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller JR, Wright AC, Bergmann JE, Gaitanaris GA (2003). "The G protein-coupled receptor repertoires of human and mouse". Proc. Natl. Acad. Sci. U.S.A. 100 (8): 4903–8. doi:10.1073/pnas.0230374100. PMC 153653  . PMID 12679517.
"GPCR Reference Library". Retrieved 11 August 2008. Reference for molecular and mathematical models for the initial receptor response
"The Nobel Prize in Chemistry 2012" (PDF). Retrieved 10 October 2012.
External links[edit]
Wikimedia Commons has media related to G protein coupled receptors.
G-protein-coupled+receptors at the US National Library of Medicine Medical Subject Headings (MeSH)
GPCR Cell Line
"GPCR Database". IUPHAR Database. International Union of Basic and Clinical Pharmacology. Retrieved 11 August 2008.
"GPCRdb". Data, diagrams and web tools for G protein-coupled receptors (GPCRs). ; Munk C, Isberg V, Mordalski S, Harpsøe K, Rataj K, Hauser AS, Kolb P, Bojarski AJ, Vriend G, Gloriam DE (2016). "GPCRdb: the G Protein-Coupled Receptor Database – an Introduction". British Journal of Pharmacology. 173 (14): 2195–207. doi:10.1111/bph.13509. PMC 4919580  . PMID 27155948.
"G Protein-Coupled Receptors on the NET". Retrieved 10 November 2010. a classification of GPCRs
"PSI GPCR Network Center". Retrieved 11 July 2013. a Protein Structure Initiative:Biology Network Center aimed at determining the 3D structures of representative GPCR family proteins
show
v
t
e
Membrane proteins, receptors: cell surface receptors
G protein–coupled receptor
Class A
Eicosanoid receptor (Prostaglandin receptor)
Protease-activated receptor
Neurotransmitter receptor
Purinergic receptor
Biogenic amine receptor
Olfactory receptor
Class B
Secretin receptor
Class C
Metabotropic glutamate receptor
Class D
Pheromone receptor
Class E
cAMP receptor
Class F
Frizzled/smoothened
Ligand-gated ion channel
Purinergic receptor
Enzyme-linked receptor
Serine/threonine-specific protein kinase
Receptor tyrosine kinase
Guanylate cyclase
Other/ungrouped
Asialoglycoprotein receptor
Tumor necrosis factor receptor
Immunoglobulin superfamily
N-Acetylglucosamine receptor
Neuropilins
Transferrin receptor
EDAR
Lipoprotein receptor-related protein
Progestin and adipoQ receptor
show
v
t
e
Cell surface receptor: G protein–coupled receptors
show
Class A: Rhodopsin-like
Neurotransmitter
Adrenergic
α1 (A
B
D)
α2 (A
B
C)
β1
β2
β3
Purinergic
Adenosine (A1
A2A
A2B
A3)
P2Y (1
2
4
5
6
8
9
10
11
12
13
14)
Serotonin
(all but 5-HT3) 5-HT1 (A
B
D
E
F)
5-HT2 (A
B
C)
5-HT (4
5A
6
7)
Other
Acetylcholine (M1
M2
M3
M4
M5)
Dopamine
D1
D2
D3
D4
D5
GHB receptor
Histamine
H1
H2
H3
H4
Melatonin (1A
1B
1C)
TAAR (1
2
5
6
8
9)
Metabolites and
signaling molecules
Eicosanoid
CysLT (1
2)
LTB4
1
2
FPRL1
OXE
Prostaglandin
DP (1
2), EP (1
2
3
4), FP
Prostacyclin
Thromboxane
Other
Bile acid
Cannabinoid (CB1
CB2, GPR (18
55
119))
EBI2
Estrogen
Free fatty acid (1
2
3
4)
Hydroxycarboxylic acids
1
2
3
Lysophosphatidic acid (1
2
3
4
5
6)
Lysophospholipid (1
2
3
4
5
6
7
8)
Oxoglutarate
PAF
Sphingosine-1-phosphate (1
2
3
4
5)
Succinate
Peptide
Neuropeptide
B/W (1
2)
FF (1
2)
S
Y (1
2
4
5)
Neuromedin (B
U (1
2))
Neurotensin (1
2)
Other
Anaphylatoxin (C3a
C5a)
Angiotensin (1
2)
Apelin
Bombesin
BRS3
GRPR
NMBR)
Bradykinin (B1
B2)
Chemokine
Cholecystokinin (A
B)
Endothelin
A
B
Formyl peptide (1
2
3)
FSH
Galanin (1
2
3)
Gonadotropin-releasing hormone (1
2)
Ghrelin
Kisspeptin
Luteinizing hormone/choriogonadotropin
MAS (1
1L
D
E
F
G
X1
X2
X3
X4)
Melanocortin (1
2
3
4
5)
MCHR (1
2)
Motilin
Opioid (Delta
Kappa
Mu
Nociceptin & Zeta, but not Sigma)
Orexin (1
2)
Oxytocin
Prokineticin (1
2)
Prolactin-releasing peptide
Relaxin (1
2
3
4)
Somatostatin (1
2
3
4
5)
Tachykinin (1
2
3)
Thyrotropin
Thyrotropin-releasing hormone
Urotensin-II
Vasopressin (1A
1B
2)
Miscellaneous
Orphan
GPR (1
3
4
6
12
15
17
18
19
20
21
22
23
25
26
27
31
32
33
34
35
37
39
42
44
45
50
52
55
61
62
63
65
68
75
77
78
81
82
83
84
85
87
88
92
101
103
109A
109B
119
120
132
135
137B
139
141
142
146
148
149
150
151
152
153
160
161
162
171
173
174
176
177
182
183)
Other
Adrenomedullin
Olfactory
Opsin (3
4
5
1LW
1MW
1SW
RGR
RRH)
Protease-activated (1
2
3
4)
SREB (1
2
3)
show
Class B: Secretin-like
Adhesion
ADGRG (1
2
3
4
5
6
7)
Orphan
GPR (56
64
97
98
110
111
112
113
114
115
116
123
124
125
126
128
133
143
144
155
157)
Other
Brain-specific angiogenesis inhibitor (1
2
3)
Cadherin (1
2
3)
Calcitonin
CALCRL
CD97
Corticotropin-releasing hormone (1
2)
EMR (1
2
3)
Glucagon (GR
GIPR
GLP1R
GLP2R)
Growth-hormone-releasing hormone
PACAPR1
GPR
Latrophilin (1
2
3
ELTD1)
Methuselah-like proteins
Parathyroid hormone (1
2)
Secretin
Vasoactive intestinal peptide (1
2)
show
Class C: Metabotropic glutamate / pheromone
Taste
TAS1R (1
2
3)
TAS2R (1
3
4
5
7
8
9
10
13
14
16
19
20
30
31
38
39
40
41
42
43
45
46
50
60
Vomeronasal receptor)
Other
Calcium-sensing receptor
GABAB (1
2)
Glutamate receptor (Metabotropic glutamate (1
2
3
4
5
6
7
8))
GPRC6A
GPR (156
158
179)
RAIG (1
2
3
4)
show
Class F: Frizzled / Smoothened
Frizzled
Frizzled (1
2
3
4
5
6
7
8
9
10)
Smoothened
Smoothened
Retrieved from "https://en.wikipedia.org/w/index.php?title=G_protein–coupled_receptor&oldid=849333861"
Categories:
G protein coupled receptors
Membrane biology
Protein families
Signal transduction
Integral membrane proteins
Molecular biology
Biochemistry
Hidden categories:
All articles with dead external links
Articles with dead external links from January 2017
Articles with permanently dead external links
Use dmy dates from November 2017
All articles with unsourced statements
Articles with unsourced statements from May 2016
Articles with unsourced statements from October 2012
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
العربية
Bosanski
Català
Čeština
Dansk
Deutsch
Eesti
Ελληνικά
Español
فارسی
Français
Galego
한국어
Bahasa Indonesia
Italiano
עברית
Latina
Latviešu
Magyar
Nederlands
नेपाल भाषा
日本語
Norsk nynorsk
Polski
Português
Русский
Slovenčina
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
Svenska
ไทย
Türkçe
Українська
Tiếng Việt
中文
27 more
Edit links
This page was last edited on 8 July 2018, at 08:29 (UTC).
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

key: html

type: local

value: div

attrs: id class

values: mw-page-base noprint

values: mw-head-base noprint

value: a

attrs: id class lang

values: firstHeading firstHeading en

values: siteSub noprint

attrs: class href

values: mw-jump-link #mw-head

values: mw-jump-link #p-search

attrs: href class title

attrs: role class

values:
note
hatnote navigation-not-searchable

value: p

value: th

attrs: colspan style

value: tr

value: img

attrs: alt src width height srcset data-file-width data-file-height

attrs: href class

attrs: href title

value: sup

value: td

values:
nofollow
external text
http://pfam.xfam.org/family?acc=PF00001

values: Orientations of Proteins in Membranes database

values: background-color: #e7dcc3; border:#fafafa 2px solid; border-width:3px 2px 0 0;

values: background-color: #eee; border:#fafafa 2px solid; border-width:3px 0 0 2px;

values: infobox collapsible collapsed mw-collapsible mw-collapsed mw-made-collapsible

values: width:22em;float:none; clear:none; margin:0; border-width:0; border-collapse:collapse; text-align:left; width:100%

attrs: alt src width height class srcset data-file-width data-file-height

values:
/wiki/Membrane_receptor
mw-redirect
Membrane receptor

values: This claim needs references to reliable sources. (May 2016)

values:
noprint Inline-Template Template-Fact
white-space:nowrap;

values:
/wiki/Olfactory_receptors
mw-redirect
Olfactory receptors

values:
/wiki/Gamma-aminobutyric_acid
mw-redirect
Gamma-aminobutyric acid

values:
/wiki/Histamine_receptors
mw-redirect
Histamine receptors

values:
/wiki/Inflammatory_mediators
mw-redirect
Inflammatory mediators

values:
/wiki/Transmembrane_helix
mw-redirect
Transmembrane helix

values:
/wiki/Disulfide_bond
mw-redirect
Disulfide bond

values:
nofollow
external text
https://www.rcsb.org/structure/2BRD

values:
nofollow
external text
https://www.rcsb.org/structure/1AT9

values:
nofollow
external text
https://www.rcsb.org/structure/1AP9

values:
nofollow
external text
https://www.rcsb.org/structure/1F88

values:
nofollow
external text
https://www.rcsb.org/structure/2R4R

values:
nofollow
external text
https://www.rcsb.org/structure/2R4S

values:
nofollow
external text
https://www.rcsb.org/structure/2RH1

values:
/wiki/Ab_initio_structure_prediction
mw-redirect
Ab initio structure prediction

values: Edit section: Structure-function relationships

values:
/wiki/Metabotropic_glutamate_receptors
mw-redirect
Metabotropic glutamate receptors

values:
/wiki/Inverse_agonists
mw-redirect
Inverse agonists

values:
/wiki/Affinity_(pharmacology)
mw-redirect
Affinity (pharmacology)

values:
/wiki/Biogenic_amines
mw-redirect
Biogenic amines

values:
/wiki/Regulator_of_G_protein_signalling
mw-redirect
Regulator of G protein signalling

values: Edit section: G-protein activation/deactivation cycle

values:
/wiki/Heterotrimeric_G-protein
mw-redirect
Heterotrimeric G-protein

values:
/wiki/Beta-gamma_complex
mw-redirect
Beta-gamma complex

values:
/wiki/GTPase_activating_protein
mw-redirect
GTPase activating protein

values:
/wiki/Adenylate_cyclase
mw-redirect
Adenylate cyclase

values:
/wiki/Tertiary_structure
mw-redirect
Tertiary structure

values:
/wiki/Protein_conformation
mw-redirect
Protein conformation

values: Edit section: G-protein-dependent signaling

values:
/wiki/Splice_variant
mw-redirect
Splice variant

values:
/wiki/Plasma_membrane
mw-redirect
Plasma membrane

values: G protein-coupled inwardly-rectifying potassium channel

values:
/wiki/Voltage-dependent_calcium_channel
mw-redirect
Voltage-dependent calcium channel

values: Edit section: G-protein-independent signaling

values:
/wiki/PDZ_(biology)
mw-redirect
PDZ (biology)

values: Immunoreceptor tyrosine-based inhibitory motif

values: Edit section: GPCR-independent signaling by heterotrimeric G-proteins

values:
/wiki/Receptor_tyrosine_kinases
mw-redirect
Receptor tyrosine kinases

values:
/wiki/Cytokine_receptors
mw-redirect
Cytokine receptors

values: Guanosine nucleotide dissociation inhibitors

values:
/wiki/Protein_phosphatases
mw-redirect
Protein phosphatases

values: Edit section: Details of cAMP and PIP2 pathways

values:
/wiki/G_protein-coupled_receptors
mw-redirect
G protein-coupled receptors

values:
/wiki/Protein_Kinase_A
mw-redirect
Protein Kinase A

values: Edit section: Phosphatidylinositol signal pathway

values:
/wiki/IP3/DAG_pathway
mw-redirect
IP3/DAG pathway

values:
/wiki/IP3_receptor
mw-redirect
IP3 receptor

values:
/wiki/Protein_Kinase_C
mw-redirect
Protein Kinase C

values:
/wiki/Heterologous_desensitization
mw-redirect
Heterologous desensitization

values: Edit section: Phosphorylation by cAMP-dependent protein kinases

values: Edit section: Mechanisms of GPCR signal termination

values:
/wiki/Rate_constant
mw-redirect
Rate constant

values:
/wiki/Second_messenger
mw-redirect
Second messenger

values:
/wiki/Clathrin-mediated_endocytosis
mw-redirect
Clathrin-mediated endocytosis

values: This claim needs references to reliable sources. (October 2012)

values:
/wiki/AP2_adaptors
mw-redirect
AP2 adaptors

values:
/wiki/Vesicle_(biology)
mw-redirect
Vesicle (biology)

values: Edit section: Origin and diversification of the superfamily

values: Receptor activated solely by a synthetic ligand

values:
nofollow
external text
//doi.org/10.1126/science.1150577

attrs: alt src title width height srcset data-file-width data-file-height

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17962520

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22300046

values:
nofollow
external text
//doi.org/10.1126/science.1083853

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12869759

values:
nofollow
external text
//doi.org/10.1038/nrd2199

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17139284

values:
nofollow
external text
//doi.org/10.1038/nrd.2017.178

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/29075003

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/3113327

values:
nofollow
external text
//doi.org/10.1152/physrev.00003.2005

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16183910

values:
nofollow
external text
//doi.org/10.1016/j.cell.2017.11.033

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/29249361

values:
nofollow
external text
//doi.org/10.1016/j.ygeno.2006.04.001

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16753280

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12429062

values:
nofollow
external text
//doi.org/10.1093/protein/7.2.195

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8170923

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8081729

values:
nofollow
external text
//doi.org/10.1124/pr.57.2.5

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15914470

values:
nofollow
external text
//doi.org/10.1073/pnas.0230374100

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12679517

values:
nofollow
external text
http://icpr.jci.jx.cn/bioinfo/GPCR-CA

values:
nofollow
external text
//doi.org/10.1002/jcc.21163

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19037861

values:
nofollow
external text
//doi.org/10.1016/j.ab.2009.04.009

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19364489

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19594431

values:
nofollow
external text
//doi.org/10.1189/jlb.0712328

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23345392

values:
nofollow
external text
//doi.org/10.1016/j.yfrne.2011.07.002

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21802439

values:
nofollow
external text
//doi.org/10.1038/nrc2069

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17251915

values:
nofollow
external text
//doi.org/10.1038/nature11896

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23407534

values:
nofollow
external text
//doi.org/10.1016/j.tips.2013.11.001

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24359917

values:
nofollow
external text
//doi.org/10.1038/nature01705

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12802337

values:
nofollow
external text
//doi.org/10.1006/jmbi.1996.0328

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8676377

values:
nofollow
external text
//doi.org/10.1038/38323

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9296502

values:
nofollow
external text
//doi.org/10.1126/science.277.5332.1676

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9287223

values:
nofollow
external text
//doi.org/10.1126/science.289.5480.739

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10926528

values:
nofollow
external text
//doi.org/10.1038/nature06325

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17952055

values:
nofollow
external text
//doi.org/10.1126/science.1150609

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17962519

values:
nofollow
external text
//doi.org/10.1038/nature09648

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21228869

values:
nofollow
external text
//doi.org/10.1038/nature09665

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21228876

values:
nofollow
external text
//doi.org/10.1038/nature09746

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21228877

values:
nofollow
external text
//doi.org/10.1126/science.1202793

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21393508

values:
nofollow
external text
//doi.org/10.1038/nature10361

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21772288

values:
nofollow
external text
//doi.org/10.1016/j.str.2015.06.007

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26190572

values:
nofollow
external text
//doi.org/10.1038/nchembio.642

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21873996

values:
nofollow
external text
//doi.org/10.1126/science.2163110

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2163110

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11861753

values:
nofollow
external text
//doi.org/10.1073/pnas.1701529114

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/28223524

values:
nofollow
external text
//doi.org/10.1038/ncomms13416

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27827372

values:
nofollow
external text
//doi.org/10.1016/j.cell.2016.07.004

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27499021

values:
nofollow
external text
//doi.org/10.1210/me.2009-0473

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20019124

values:
nofollow
external text
//doi.org/10.1378/chest.124.3_suppl.18S

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12970120

values:
nofollow
external text
//doi.org/10.1073/pnas.0607116103

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17095603

values:
nofollow
http://cogprints.org/4095/
external text

values:
nofollow
external text
//doi.org/10.1155/2012/341282

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23056062

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8807851

values:
nofollow
external text
//doi.org/10.1074/jbc.M202744200

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12177051

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11053129

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14744258

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23532739

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14499340

values:
nofollow
external text
//doi.org/10.1074/jbc.272.1.5

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8995214

values:
nofollow
external text
//doi.org/10.1074/jbc.M002581200

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10770944

values:
nofollow
external text
//doi.org/10.1073/pnas.96.7.3712

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10097102

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10939334

values:
nofollow
external text
//doi.org/10.1038/25354

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9872316

values:
nofollow
external text
//doi.org/10.1371/journal.pone.0029817

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22238661

values:
nofollow
external text
//doi.org/10.1093/molbev/msr061

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21402729

values: -moz-column-width: 33em; -webkit-column-width: 33em; column-width: 33em; list-style-type: decimal;

values:
nofollow
external text
http://www.bio-balance.com/Ref.htm

values: commons:Category:G protein coupled receptors

values:
nofollow
external text
http://docs.gpcrdb.org/about.html

values:
nofollow
external text
//doi.org/10.1111/bph.13509

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27155948

values:
nofollow
external text
http://www.gproteincoupledreceptors.net

values:
nofollow
external text
http://gpcr.scripps.edu

values:
row
navbox-group
width:1%;background-color: AntiqueWhite

values:
/wiki/CAMP_receptor
mw-redirect
CAMP receptor

values:
/wiki/Tumor_necrosis_factor_receptor
mw-redirect
Tumor necrosis factor receptor

values: nowraplinks hlist collapsible autocollapse navbox-inner mw-collapsible mw-made-collapsible mw-collapsed

values: Template talk:G protein-coupled receptors

values:
/wiki/EP1_receptor
mw-redirect
EP1 receptor

values:
/wiki/Prostaglandin_E_receptor_3
mw-redirect
Prostaglandin E receptor 3

values:
/wiki/EP4_receptor
mw-redirect
EP4 receptor

values:
/wiki/Angiotensin_receptor
mw-redirect
Angiotensin receptor

values: Melanin-concentrating hormone receptor 1

values: Melanin-concentrating hormone receptor 2

values: Relaxin/insulin-like family peptide receptor 1

values: Relaxin/insulin-like family peptide receptor 2

values: Relaxin/insulin-like family peptide receptor 3

values: Relaxin/insulin-like family peptide receptor 4

values:
/wiki/Arginine_vasopressin_receptor_1A
mw-redirect
Arginine vasopressin receptor 1A

values:
/wiki/Arginine_vasopressin_receptor_1B
mw-redirect
Arginine vasopressin receptor 1B

values:
/wiki/Arginine_vasopressin_receptor_2
mw-redirect
Arginine vasopressin receptor 2

values: Pyroglutamylated RFamide peptide receptor

values:
/wiki/Niacin_receptor_1
mw-redirect
Niacin receptor 1

values:
/wiki/Niacin_receptor_2
mw-redirect
Niacin receptor 2

values:
/wiki/Protease_activated_receptor_2
mw-redirect
Protease activated receptor 2

values: nowraplinks collapsible autocollapse navbox-subgroup mw-collapsible mw-made-collapsible mw-collapsed

values: Corticotropin releasing hormone receptor 1

values: Corticotropin releasing hormone receptor 2

values: EGF module-containing mucin-like hormone receptor

values:
/wiki/Latrophilin_receptor
mw-redirect
Latrophilin receptor

values: Retinoic acid-inducible orphan G protein-coupled receptor

values: nowraplinks collapsible collapsed navbox-inner mw-collapsible mw-collapsed mw-made-collapsible

values: Category:All articles with dead external links

values: Category:Articles with dead external links from January 2017

values: Category:Articles with permanently dead external links

values: Category:Use dmy dates from November 2017

values: Category:All articles with unsourced statements

values: Category:Articles with unsourced statements from May 2016

values: Category:Articles with unsourced statements from October 2012

values: Discussion about edits from this IP address [ctrl-alt-n]

values: Find background information on current events

values: Guidance on how to use and edit Wikipedia

values: About the project, what you can do, where to find things

values: A list of recent changes in the wiki [ctrl-alt-r]

values: portal navigation p-interaction p-interaction-label

values: List of all English Wikipedia pages containing links to this page [ctrl-alt-j]

values: Recent changes in pages linked from this page [ctrl-alt-k]

values:
/wiki/Wikipedia:File_Upload_Wizard
Upload files [ctrl-alt-u]
u

values: A list of all special pages [ctrl-alt-q]

values: Permanent link to this revision of the page

values: Link to connected data repository item [ctrl-alt-g]

values: Printable version of this page [ctrl-alt-p]

values: portal navigation p-wikibase-otherprojects p-wikibase-otherprojects-label

values: مستقبل مقترن بالبروتين ج – Arabic

values: Receptori spregnuti sa G-proteinom – Bosnian

values:
interlanguage-link interwiki-bs
display: none;

values: Receptor acoblat a proteïnes G – Catalan

values:
interlanguage-link interwiki-ca
display: none;

values:
interlanguage-link interwiki-cs
display: none;

values:
interlanguage-link interwiki-da
display: none;

values: interlanguage-link interwiki-de badge-Q17437796 badge-featuredarticle

values:
interlanguage-link interwiki-et
display: none;

values: Υποδοχέας συζευγμένος με πρωτεΐνη G – Greek

values:
interlanguage-link interwiki-el
display: none;

values: Receptor acoplado a proteínas G – Spanish

values: گیرنده جفت‌شونده با پروتئین جی – Persian

values:
interlanguage-link interwiki-fa
display: none;

values: Récepteur couplé aux protéines G – French

values: Receptor acoplado á proteína G – Galician

values:
interlanguage-link interwiki-gl
display: none;

values: G 단백질 연결 수용체 – Korean

values:
interlanguage-link interwiki-ko
display: none;

values: Reseptor terhubung-protein G – Indonesian

values: Recettori accoppiati a proteine G – Italian

values:
interlanguage-link interwiki-it
display: none;

values: קולטן המצומד לחלבון G – Hebrew

values:
interlanguage-link interwiki-he
display: none;

values: Receptorium proteino G copulatum – Latin

values:
interlanguage-link interwiki-la
display: none;

values: Ar G proteīniem saistītie receptori – Latvian

values:
interlanguage-link interwiki-lv
display: none;

values:
interlanguage-link interwiki-hu
display: none;

values:
interlanguage-link interwiki-nl
display: none;

values: जि प्रोटिन कपल्ड रिसेप्टर – Newari

values:
interlanguage-link interwiki-new
display: none;

values: Gタンパク質共役受容体 – Japanese

values:
interlanguage-link interwiki-ja
display: none;

values: G-protein-kopla reseptor – Norwegian Nynorsk

values:
interlanguage-link interwiki-nn
display: none;

values: Receptory sprzężone z białkami G – Polish

values:
interlanguage-link interwiki-pl
display: none;

values: Receptor acoplado à proteína G – Portuguese

values:
https://ru.wikipedia.org/wiki/GPCR
GPCR – Russian
ru
ru
interlanguage-link-target

values: Receptor spriahnutý s G-proteínmi – Slovak

values:
interlanguage-link interwiki-sk
display: none;

values: interlanguage-link interwiki-sr badge-Q17437796 badge-featuredarticle

values: G protein spregnuti receptori – Serbo-Croatian

values:
interlanguage-link interwiki-sh
display: none;

values: G-proteiinikytkentäinen reseptori – Finnish

values:
interlanguage-link interwiki-fi
display: none;

values:
interlanguage-link interwiki-sv
display: none;

values: หน่วยรับที่จับคู่กับจีโปรตีน – Thai

values:
interlanguage-link interwiki-th
display: none;

values:
interlanguage-link interwiki-tr
display: none;

values: G-білокспряжені рецептори – Ukrainian

values:
interlanguage-link interwiki-uk
display: none;

values: Thụ thể bắt cặp với G protein – Vietnamese

values:
interlanguage-link interwiki-vi
display: none;

values: All languages (initial selection from common choices by you and others)

values: /static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x

values: /static/images/poweredby_mediawiki_132x47.png 1.5x, /static/images/poweredby_mediawiki_176x62.png 2x

values:
suggestions
display: none; font-size: 13px;

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-G_protein–coupled_receptor rootpage-G_protein–coupled_receptor skin-vector action-view